{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-23-047683","form_type":"8-K","ticker":"HRMY","cik":"0001802665","company_name":"Harmony Biosciences Holdings, Inc.","filed_at":"2023-10-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.527712+00:00","generated_at":"2026-06-10T01:45:26.556936+00:00","sec_items":["2.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Harmony Biosciences completes acquisition of Zynerba for $60M cash plus up to $140M in CVRs","bullets":["Purchase price of $1.1059 per share in cash (approx. $60M aggregate) plus one CVR per share worth up to $2.5444.","Tender offer received 52.3% of Zynerba shares; merger completed on Oct 10, 2023; Zynerba now wholly owned subsidiary.","Lead candidate Zygel is a synthetic cannabidiol gel in Phase 3 for Fragile X syndrome; also studied in 22q deletion syndrome.","Zygel granted FDA Fast Track for FXS and orphan designation in US and EU; potential to address ~160,000 US patients.","Zynerba common stock to be delisted from Nasdaq; Harmony diversifies pipeline beyond sleep/wake therapies."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-23-047683","json":"https://secwatch.observer/filing/0001140361-23-047683.json","markdown":"https://secwatch.observer/filing/0001140361-23-047683.md","text":"https://secwatch.observer/filing/0001140361-23-047683.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1802665/000114036123047683/0001140361-23-047683-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1802665/000114036123047683/ny20012277x2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T01:45:26.556936+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9a4bd73a39e0f338fcbf3f40e9249eb787f9b922","claim":"Harmony Biosciences Holdings, Inc. completed an acquisition involving Zynerba Pharmaceuticals, Inc. for $1.1059 per Share in cash plus one contingent value right per Share (closed 2023-10-10).","evidence_excerpt":"commenced a tender offer (the “Offer”) to acquire all of the outstanding shares of common stock of Zynerba , par value $0.001 per share (the “Shares”), at a price of (i) $ 1.1059 per Share (the “Closing Amount”), in cash, subject to any applicable withholding of taxes and without interest, plus (ii) one contingent value right (each, a “CVR”) per Share ,","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1802665/000114036123047683/0001140361-23-047683-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"acquisition"},{"label":"Counterparty","value":"Zynerba Pharmaceuticals, Inc."},{"label":"Consideration","value":"$1.1059 per Share in cash plus one contingent value right per Share"},{"label":"Closing","value":"2023-10-10"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}